The Art of Conquering Cancer

See how creativity sparks breakthroughs for researchers like Dr. Lillian Siu and Dr. Lawson Eng, and transforms outcomes for patients like Allen Chankowsky.
Dr. Anastasia Tikhonova embodies The Art of Conquering Cancer. She and her team discovered mechanisms responsible for bone defects suffered by many leukemia patients after chemotherapy. They found that some chemotherapy drugs permanently alter the DNA in stem cells that give rise to bone cells.

The Tikhonova Lab is now working on creative ways to reverse these molecular changes and reduce bone defects, which would vastly improve quality of life for leukemia survivors.
Creativity is at the heart of everything we do at The Princess Margaret. Having the freedom to explore keeps our experts at the forefront, whether they are developing life-saving therapies, innovating new models of care or rethinking the design needs of our patient care facilities.

Creative solutions are needed now more than ever. Cancer is Canada’s leading cause of death and the second leading cause of death globally. 2 in 5 Canadians will be diagnosed with cancer in their lifetime, and the risk increases with age, which is worrisome since Canada’s population is getting older. By 2030, nearly 25% of Canadians will be over the age of 65, a number which was closer to 14% in 2010.

However, there is hope. It comes from our incredible community of supporters. Every time someone purchases a lottery ticket, sponsors a friend in one of our events, makes an annual or monthly contribution, pledges a multi-year major gift, or gives to The Princess Margaret in their Will, they support life-saving, innovative research.

Thanks to our community of supporters, this past year the Foundation raised $284 million, our highest revenue ever. This generosity is what makes creativity and the transformation of cancer outcomes possible. Donations from our community have enabled our researchers to develop a simple blood test called liquid biopsy. The test not only has the potential to detect cancer radically earlier, sometimes before symptoms even appear, but also provides clinicians the detailed information they need to determine the most effective therapy for each patient.

In the future, again because of donations, we also believe that toxic chemotherapy will be replaced by innovative new treatments with fewer side effects.

Throughout this report, you will see creativity and community in action. You will read about Allen Chankowsky, and how next-generation treatments saved his life despite a Stage 4 diagnosis of a rare and aggressive head and neck cancer. You will read about leading-edge multiple myeloma research made possible by a $9.2 million (CAD) gift from the U.S.-based Paula and Rodger Riney Foundation—research seeking breakthroughs for an as-yet incurable cancer. You will read about a Ride to Conquer Cancer participant who wanted to give back to the care team that treated his wife’s aggressive pancreatic cancer, and who went on to help his team raise a record-setting $2.9 million in support of life-saving research.

All of this and more are signs that the future is bright. Our dedicated community, combined with the excellence, determination and creative thinking of the team at Princess Margaret Cancer Centre, is building a movement around cancer. Together, we can all make a profound impact, prolonging lives and giving people more time with their loved ones, both here and around the world. With the power of our movement, we will achieve our vision of Conquering Cancer In Our Lifetime.

“Creative solutions are needed now more than ever. Cancer is Canada’s leading cause of death and the second leading cause of death globally.” – Dr. Miyo Yamashita
Building a World Free From the Fear of Cancer

Each day, an average of 617 Canadians will hear those three devastating words: “You have cancer.” In that moment, their worlds change, and a life-altering journey begins.

Cancer is the leading cause of death in Canada. It is estimated that 2 in 5 Canadians will develop cancer in their lifetime and about one in four will die from the disease. The number of cases diagnosed annually is increasing, highlighting the importance of cancer prevention and early detection.

Princess Margaret Cancer Centre and The Princess Margaret Cancer Foundation at University Health Network (UHN) are wholly committed to Conquering Cancer. From launching the Princess Margaret Cancer Care Network, which sees centres sharing expertise and resources, to the ALLO@Home program, which allows alloeneic stem cell transplant patients to receive care at home, The Princess Margaret continues to be a world-leading example of collaboration and innovation.

These advancements are made possible through the exceptional work of TeamUHN, which weathered a range of challenges this year with ongoing COVID-19 variants and challenging economic conditions. We are grateful for the generosity of The Princess Margaret Cancer Foundation and its community of donors who empower the best in science and innovation. We are also thankful for the leadership of the Board of Trustees and Foundation Board over the past year.

As Canada’s top academic health sciences centre, UHN is looking forward to building a world free from the fear of cancer. The tremendous work of The Princess Margaret brings us closer each day to achieving our shared dream. From launching the Princess Margaret Cancer Care Network, which sees centres sharing expertise and resources, to the ALLO@Home program, which allows alloeneic stem cell transplant patients to receive care at home, The Princess Margaret continues to be a world-leading example of collaboration and innovation.

These advancements are made possible through the exceptional work of TeamUHN, which weathered a range of challenges this year with ongoing COVID-19 variants and challenging economic conditions. We are grateful for the generosity of The Princess Margaret Cancer Foundation and its community of donors who empower the best in science and innovation. We are also thankful for the leadership of the Board of Trustees and Foundation Board over the past year.

As Canada’s top academic health sciences centre, UHN is looking forward to building a world free from the fear of cancer. The tremendous work of The Princess Margaret brings us closer each day to achieving our shared dream.

Transforming Cancer Outcomes

We look back on the past year with immense gratitude. We not only survived the third year of the COVID-19 pandemic, but thrived, thanks to the commitment and dedication of our community of supporters and volunteers, as well as our patients, staff, researchers, clinicians and learners.

In our effort to be the world’s leading cancer centre, The Princess Margaret relies on the generous support of The Princess Margaret Cancer Foundation for the continued success of our programs, research and innovation. The Foundation had another amazing year with the robust return of all in-person events, and the ongoing success of the Lottery and Major and Estate Giving. Among the year’s many highlights was the generous $9.2 million (CAD) donation from the Paula and Rodger Riney Foundation to support multiple myeloma research. This grant is the first in Canada from this U.S.-based Foundation and will fund four projects with potential clinical impact in Canada from this U.S.-based Foundation and will fund four projects with potential clinical impact in Canada from this U.S.-based Foundation and will fund four projects with potential clinical impact in Canada from this U.S.-based Foundation and will fund four projects with potential clinical impact in Canada from this U.S.-based Foundation and will fund four projects with potential clinical impact in Canada from this U.S.-based Foundation and will fund four projects with potential clinical impact in Canada from this U.S.-based Foundation and will fund four projects with potential clinical impact in Canada from this U.S.-based Foundation and will fund four projects with potential clinical impact in Canada from this U.S.-based Foundation and will fund four projects with potential clinical impact in Canada from this U.S.-based Foundation and will fund four projects with potential clinical impact in Canada from this U.S.-based Foundation and will fund four projects with potential clinical impact in Canada from this U.S.-based Foundation and will fund four projects with potential clinical impact in Canada from this U.S.-based Foundation and will fund four projects with potential clinical impact in Canada from this U.S.-based Foundation and will fund four projects with potential clinical impact in Canada from this U.S.-based Foundation and will fund four projects with potential clinical impact in Canada from this U.S.-based Foundation and will fund four projects with potential clinical impact in Canada. The Princess Margaret is almost 23%, which far exceeds the national averages of Canada, the United States and the UK.

At The Princess Margaret, we are “Always Moving Forward.” We could not do it without you, and we remain extremely grateful for the dedicated support of all our patients, families, donors and supporters and look forward to our continued partnerships.

Our Global Oncology team added cancer centres in Kenya, Australia and Malaysia to our list of partners, and we welcomed the Southlake Stratton Cancer Centre and Grand River Regional Cancer Program to the new Princess Margaret Cancer Care Network.

We look forward to focusing on our refreshed strategic priorities which include: an exceptional patient experience; high-impact solutions such as augmented human intelligence, which will revolutionize decision-making in cancer care; proton therapy, which will advance precision radiation treatments; pathways to cure such as early cancer detection; and high-definition therapeutics that move beyond chemotherapy, embracing multi-omic analysis of each cancer, immune therapies and surgical technical innovation.

Our scientists will explore beyond the cutting edge, boldly tackling the toughest cancer challenges. Finally, we will prioritize recruitment and diversity in clinical trials and basic research to continue to create more equitable treatments. Patient participation in clinical trials at The Princess Margaret is almost 23%, which far exceeds the national averages of Canada, the United States and the UK.

At The Princess Margaret, we are “Always Moving Forward.” We could not do it without you, and we remain extremely grateful for the dedicated support of all our patients, families, donors and supporters and look forward to our continued partnerships.
Embracing Creativity in the Realm of Cancer Research

“Groundbreaking results happen when the best scientists in the world can pursue their curiosity together, in a collaborative community—supported by access to long-term, undesignated funding.”

—Dr. Aaron Schimmer
Research Director, Princess Margaret Cancer Centre

A historic, undesignated $50 million gift made by La Fondation Emmanuelle Gattuso and The Slaight Family Foundation in honour of the late Allan Slaight, the Canadian business legend and philanthropist, is transforming the future of discovery research at The Princess Margaret. Some of the biggest breakthroughs in cancer research, leading to the greatest advancements in treatment and patient care, come from undesignated donations.

“We are immensely grateful for their transformational gift and commitment to not only support discovery research—the exploration of big and bold ideas that could lead to treatments and outcomes that we’ve yet to imagine—but also to empower the next generation of researchers,” said Dr. Aaron Schimmer, Research Director at Princess Margaret Cancer Centre.

“This gift will enable us to recruit some of the brightest minds in cancer research, education, and care from around the world, and create a critical mass of Allan Slaight Scientists who embrace free-thinking and approach their work in creative and unconventional ways. Ultimately, their exploration and findings will benefit patients and their loved ones at The Princess Margaret and around the world.”

The generosity of The Princess Margaret Cancer Foundation’s donors, including La Fondation Emmanuelle Gattuso, The Slaight Family Foundation, and other supporters, drives transformational breakthroughs in cancer research, treatment and patient care. The passionate commitment of our community to the shared vision of Conquering Cancer In Our Lifetime empowers our world-renowned researchers to leap into the power of creativity and explore the intersection of art and science in their work.

The following four projects led by Dr. Shane Harding, Dr. Ming-Sound Tsao, Dr. Kristin Hope, and Dr. Razq Hakem are only a few examples of the transformative research projects underway at The Princess Margaret that have led to breakthrough discoveries with the potential to change the future of cancer care.

You can learn more about research underway at The Princess Margaret by visiting thepmcf.ca/Media-Supporter-Stories.
Exposing the Role of Micronuclei in Cancer Biology

Research led by Dr. Shane Harding sheds new light on the role of micronuclei—small structures in cells that contain fragments of genetic material—in response to DNA damage. Micronuclei form in cells that have experienced stress and are known to play a role in inflammation following DNA damage. This can speed up cancer development and determine the effectiveness of cancer treatments. When micronuclei rupture, a protein called cGAS binds to them and initiates an inflammatory response. However, this does not always happen.

Dr. Harding and team found that different types of stress and DNA damage-inducing treatments affect the ability of micronuclei to initiate inflammatory responses. They also found that certain features of the genetic material within micronuclei can affect the inflammatory response.

“This work has important implications for how the genetic material is arranged in the cell before and after exposure to cancer treatments that damage DNA. We also think micronuclei features may determine how cancers develop in the first place,” explains Dr. Harding. “Understanding these molecular processes could lead to new ways to harness the impacts of micronuclei on cellular biology, and could ultimately lead to better cancer treatments with fewer side effects.”

New Target for Blood Cancers

Despite broad progress in care for blood-based cancers in recent years, the long-term prognosis for patients with acute myeloid leukemia (AML) is poor. Less than a quarter of patients with AML survive beyond five years. Part of the issue is that AML is caused by stem cells that too often become drug resistant, making it difficult for researchers to design effective therapies.

To find new ways to treat AML, Dr. Kristin Hope and her team have been studying a group of proteins that play a role in how cells function. The proteins, called RNA splicing factors, stop behaving normally if the cells are cancerous. Dr. Hope’s team has found that patients with AML tend to face poorer outcomes if they have elevated levels of a specific splicing factor called RBM17.

In particular, the team has discovered that the presence of RBM17 seems to allow a gene called EIF4A2 to proliferate in the blood. This gene seems to help leukemic cells multiply. In experimental models, Dr. Hope and her team have found that by eliminating either RBM17 or EIF4A2, they were able to reduce cancer growth.

The discovery is important because it suggests that therapies targeting RBM17 and EIF4A2 might be more effective. Developing such therapies is the next step toward a potential breakthrough for AML patients.

Uncovering New Vulnerabilities in Cancers with BRCA1 Mutations

When the BRCA1 gene is functioning properly, it plays a key role in repairing damaged DNA. However, mutations in the gene can also lead to an increased risk of developing breast and ovarian cancer.

Mutant BRCA1 cancers are challenging for health care teams as they tend to resist conventional therapy and often recur. As such, many researchers share the goal of finding better treatments for these cancers. Dr. Razq Hakem and his dedicated team at The Princess Margaret are making progress.

Within a cancer cell, the death of one single gene, including BRCA1, does not kill the cell overall. However, the death of two linked genes, a pair known as synthetic lethal partners, is more likely to result in the death of the cancer cell as a whole. This is known as synthetic lethality.

Using advanced genetic techniques, Dr. Razq Hakem and his team identified the gene MEPCE as a synthetic lethal partner of BRCA1.

Follow-up studies showed that the loss of MEPCE in BRCA1-mutated breast and ovarian cancer cells impaired the ability of those cancer cells to proliferate. The research also revealed other molecules involved in these processes that could be potential targets for new therapies. These targets could create new potential for more successfully treating BRCA1-mutant tumours.

Predicting Outcomes in Lung Cancer

Lung cancer is the leading cause of cancer-related deaths globally. Most anti-cancer agents focus on genetic mutations, but many lung tumours do not contain these targetable mutations. Therefore, a strong clinical need for new effective anti-cancer agents still remains.

To address this, a research team led by Drs. Ming-Sound Tsao and Michael Moran implanted 137 tumours from patients with adenocarcinoma and squamous cell cancer into laboratory models known as patient-derived xenografts. The team extensively studied the genetics and proteins present in the tumours and used this information to construct molecular profiles of the tumours. They found that the laboratory models closely mirrored human disease, with genetic mutations that are known to promote cancer cell growth.

The team then examined the protein makeup of the laboratory tumour models and discovered three adenocarcinoma and two squamous cell carcinoma prototypes (different protein profiles), that were each associated with different patient outcomes.

Together, they demonstrated that the models closely reflected non-small cell lung cancer in patients and could be used to provide new insight into treatment outcomes.

By looking at the genetics and the protein landscape of these tumours, researchers hope to be able to identify new anti-cancer therapies that go beyond targeting single mutations.
Always Moving Forward

We are pleased to present Princess Margaret Cancer Centre’s strategic priorities refreshed in 2023.

Strategic Roadmap

This ambitious strategic plan has three core themes: Elevate, Explore and Inspire.

Elevate
We will take our exceptional patient experience to new heights while building a confident and healthy workplace for all.

Explore
We will create and accelerate the highest impact solutions in cancer care, research and education.

Inspire
We will foster and deepen relationships with our partners across the world and revolutionize new pathways to cures.

Enhanced by Our Core Priorities

Embed IDEA
We will ensure that inclusion, diversity, equity, accessibility and anti-racism (IDEAA) are integrated into everything we do. We will be recognized leaders in embedding IDEA in cancer care, research and education.

Diversified Revenue
We will purposefully and rapidly expand revenue sources outside of traditional public funding that can be re-invested in support of cancer research and education.

Smart Capacity
We will identify and grow clinical areas that best showcase the specialized and differentiating skills available at Princess Margaret Cancer Centre and do so in a financially sustainable way.

Digital and Data Enabled
We will leverage digital technologies and data science to cultivate large clinical and research databases. This will enable us to advance business, clinical and research intelligence at Princess Margaret Cancer Centre—ushering in a new era of progress and innovation.

To see the strategic plan in full, visit:uhn.ca/PrincessMargaret/Strategy
In February, Paula and Rodger Riney, through the Paula and Rodger Riney Foundation, made a generous $9.2 million (CAD) commitment to Princess Margaret Cancer Centre at University Health Network (UHN) to support multiple myeloma research. Multiple myeloma is a blood cancer caused by abnormal plasma cells proliferating in the bone marrow. An estimated 4,000 Canadians were diagnosed with this cancer in 2022, and an estimated 1,650 Canadians died from it.

Thanks to a generous $9.2 million (CAD) donation from the Paula and Rodger Riney Foundation, The Princess Margaret will remain at the forefront of multiple myeloma research.

However, survival outcomes in multiple myeloma have improved substantially over the past decade due to the advent of new therapeutics. The Princess Margaret has been at the forefront of these developments. Nevertheless, a cure remains elusive and drug-related side effects continue to take a toll on patients, underscoring the need for more innovative therapies.

The very generous commitment of the Paula and Rodger Riney Foundation will make an incalculable difference in advancing research in our core strengths including diagnostics, antibody treatment, immunotherapies and cell-free genomics.”

–Dr. Keith Stewart
Vice-President, Cancer and Director, Princess Margaret Cancer Program, University Health Network

The grant from the Paula and Rodger Riney Foundation is the first in Canada from the U.S.-based Foundation, and will fund four projects with potential clinical impact being developed by world-leading researchers at The Princess Margaret.

These projects include improving multiple myeloma surveillance using plasma whole-genome sequencing, led by Dr. Trevor Pugh and Dr. Suzanne Trudel; testing new bi-specific antibodies harnessing natural killer (NK) cells with the potential to kill myeloma cells, led by Dr. Rodger Tiedemann; advancing Ptk7ye inhibition as a target in myeloma, led by Dr. Keith Stewart; and developing a new T-cell-based therapeutic for myeloma led by Dr. Tak Mak.

Rodger Riney, who is based in St. Louis, Missouri, said his own experience with myeloma motivated him to support organizations at the leading edge of research. “There is no time to waste in the pursuit of better understanding, treatment, and cures for this cancer. We applaud The Princess Margaret for its innovative work in this field which will save patients’ lives and we hope our gift will inspire others.”

Other notable Paula and Rodger Riney Foundation grant recipients include the Dana-Farber Cancer Institute, the Massachusetts General Cancer Center and the Mayo Clinic.

The Princess Margaret has one of the largest multiple myeloma programs worldwide and runs more than 40 myeloma clinical trials every year. It also conducts 300 stem cell transplants for myeloma patients annually. Toronto’s highly diverse population ensures that the research supported by the Paula and Rodger Riney Foundation benefits a broad spectrum of patients.
Instilling Confidence and Reflecting Excellence

We launched our $50 million Space Transformation Campaign so that our physical space would match the world-class cancer care at The Princess Margaret. Our goals were ambitious: we wanted to create a healing and therapeutic environment that supports our patients, caregivers and staff. We wanted to simplify and improve the experience for patients and their families today and ensure flexibility for the future.

As we got started, extensive consultations with patients, caregivers and staff all delivered the same message—we need calming, modern spaces that facilitate the best cancer care and research.

Our space now reflects the excellence of The Princess Margaret. It is bright and airy, accessible, easy to navigate and filled with art, light and music. Essential services like the Myhal Family Blood Collection/ECG Lab and Outpatient Pharmacy are much larger and, along with re-designed clinics like the Gynecologic Oncology Clinic, are better for both patients and staff.

Relaxing lounges, intuitive wayfinding, an accessible ramp on University Avenue and the significantly expanded Patient and Family Library all contribute to a truly therapeutic and healing environment, critical for the thousands of new patients who are referred every year to the Princess Margaret Cancer Centre.

Our Space Transformation was made possible thanks to the incredible generosity of our donors along with wonderful leadership from our dedicated volunteers and Foundation Board. We also extend our deepest gratitude to Tom Ehrlich for his unflagging commitment and tireless leadership of the Space Transformation Campaign. By creating a physical environment that instills confidence and reflects the excellence of The Princess Margaret, this Campaign will have a lasting impact on care, outcomes and quality of life for cancer patients and their loved ones.

To create opportunities for reflection and delight through visual art, we have new gallery spaces that will be curated by partner artists and organizations in the years to come. As we begin, the Art Gallery of Ontario has generously loaned us two spectacular paintings and artist Steve Driscoll has contributed one of his signature landscape paintings.

Leveraging the Power of Art

To learn more or to make a gift to the Space Transformation Campaign or new building projects, please contact Malka Greene, Senior Director, Major Gifts, at malka.greene@thepmcf.ca.
A Legacy of Giving

How one family’s generosity could lead to new insights in genetics, early detection and equity in cancer care.

When Goldie Feldman emigrated from Poland to Canada in 1935, at the tender age of six, her family had little in the way of material possessions. They were, however, rich in community—something she always remembered, as her fortunes rose. In fact, philanthropy was one of her lifelong joys, a passion she passed on to each of her five children—David, Karen, Donna, Lindy and Barry.

Among their many causes, the Green family has generously contributed over $4.5 million to The Princess Margaret. In 2021, the $1 million Karen Green and George Fischer Family Genomics and Genetics Fund was established to foster life-saving interventions for metastatic breast cancer. The poignant donation, in honour of Karen, who sadly succumbed to the illness, was matched by Goldie with an additional $1 million before she herself passed away in 2022 at the age of 94.

To carry on Goldie’s legacy of philanthropy, Lindy Green and her partner Sam Chaiton gave $1 million to early detection research and $1 million to create The Princess Margaret’s Health Equity Grand Challenge. The latter supports three cutting-edge projects. Led by Drs. Neil Fleshner, Shabbir Alibhai and Tulin Cil, the initiatives aim to eliminate disparities in cancer care that disproportionately impact Black, Indigenous and people of colour.

One in four Black men develop prostate cancer, a two-fold increased risk compared to non-Black men.”

–Dr. Neil Fleshner

Dr. Shabbir Alibhai, Senior Scientist and Geriatric Oncologist, and his collaborators across the country are studying the lived experience of racialized older Canadians with cancer. Among their questions: why are racialized older adults less likely to be invited to participate in clinical trials. “To improve cancer treatment for this population, we need to change this,” says Dr. Alibhai.

Dr. Tulin Cil, a surgeon and researcher who holds the Gattuso Chair in Breast Surgical Oncology, is collaborating with Dr. Funmilola Wuraola, a surgical oncologist at the Obafemi Awolowo University Teaching Hospital (OAUTH) in Nigeria. Nigerian women are diagnosed at a younger age and later stage of breast cancer compared to their North American or European counterparts, and yet have limited access to the life-saving genetic testing that might better detect the illness.

“I hope our research will lay the foundation for breast cancer genetic testing as a standard of care in Nigeria,” says Dr. Cil.

Jacqueline Silvera, UHN’s Director of Inclusion, Diversity, Equity, Accessibility and Anti-Racism, is unequivocal about the value of the family’s support. She says, “The donor’s focus on equity is invaluable to the health of the communities served by The Princess Margaret, as well as to all cancer patients across Canada and around the world.”
It truly is a bold investment in our future and future generations. After all, without our health, we have nothing.”

To shape the future of cancer care, many donors participate in our Invest in Research program. They get a front-row seat to the brilliant minds at The Princess Margaret who are developing high-risk, high-reward projects that might not otherwise receive funding from traditional sources.

Each year, our Invest in Research donors, along with our research department, vote to decide which new and innovative cancer research projects receive a prestigious $100,000 grant.

To date, Invest in Research donors have contributed a total of $2.8 million, which has funded the innovative initiatives of more than 25 researchers. Thank you to our Invest in Research donors. Your support will help us to accelerate the transformation of cancer outcomes.

Thanks to generous donor support, we’ve awarded grants to three promising projects this past year:

**Dr. Cheryl Arrowsmith**
Senior Scientist

Dr. Arrowsmith and her team are developing a treatment that can potentially kill cancer cells that depend on the NSD2 protein in Acute Lymphoblastic Leukemia, one of the deadliest leukemias in children.

**Dr. Naoto Hirano**
Senior Scientist

Bi-specific T-cell engagers (BiTEs) are an exciting new form of immunotherapy that use antibodies to redirect a patient’s T-cells to kill cancer cells. Dr. Hirano and his team are developing a BiTE therapy for Acute Myeloid Leukemia, a blood cancer with low rates of survival and few treatment options beyond chemotherapy.

**Dr. Mohammad Mazhab-Jafari**
Senior Scientist

Fatty acid synthesis is a process that’s overactive in cancer, initiated by a chemical reaction caused by an enzyme called FASN. Dr. Mazhab-Jafari and his team aim to fully understand how FASN works at the atomic level, which has never been done before.

To learn more about these novel projects and the impact that you can make, visit [thepmcf.ca/Invest-In-Research](http://thepmcf.ca/Invest-In-Research).

Ready to invest?
Contact Jared Drewnowsky, Associate Director, Major Gifts, at jared.drewnowsky@thepmcf.ca.

“"It truly is a bold investment in our future and future generations. After all, without our health, we have nothing.”

–Rhonda Sheff, Invest in Research donor
In Loving Honour of George and Helen Vari

In 1961, Drs. James Till and Ernest McCulloch revolutionized cancer medicine by proving the existence of stem cells. Their research at The Princess Margaret was transformational—it helped advance exploratory treatments, including bone marrow transplantation, and some of Canada’s first clinical trial programs.

In honour of these influential figures, The Princess Margaret Cancer Foundation launched the Till & McCulloch Society in 2015. It recognizes the many individuals, foundations, corporations, and unions who have cumulatively donated $1 million or more. Together, their support provides the world-renowned scientists and clinicians at the Cancer Centre with resources critical to continue making life-saving advances in cancer research, education, and care.

Among our visionary society members is the George and Helen Vari Foundation, established in 1984 by the late Helen and George Vari. These devoted philanthropists were incredibly passionate about research and education. The Foundation has been boosting the careers of young scientists for decades by providing funding for educational initiatives, ranging from discovery science to clinical research. Their Foundation’s support is helping The Princess Margaret to achieve excellence as one of the top 5 cancer research centres in the world.

Along with supporting the leaders of tomorrow, the George and Helen Vari Foundation has increased research capacity by supporting many initiatives, from funding cancer research to generate breakthroughs that will revolutionize patient care in Canada and around the world. Thank you all for playing an invaluable role in our vision to Conquer Cancer In Our Lifetime.

Helen and George immigrated from Hungary in the 1950s and were incredibly grateful for the opportunities and support they received in Canada. Their unwavering belief in this country’s value and the potential for its future made donating to The Princess Margaret an important part of their legacy. Now, under the leadership of Agnes Hilkene, Victoria De Luca and Alexandra Hilkene, the Foundation remains committed to ensuring that emerging leaders can achieve their full potential.

Among our visionary society members is the George and Helen Vari Foundation, established in 1984 by the late Helen and George Vari. These devoted philanthropists were incredibly passionate about research and education. The Foundation has been boosting the careers of young scientists for decades by providing funding for educational initiatives, ranging from discovery science to clinical research. Their Foundation’s support is helping The Princess Margaret to achieve excellence as one of the top 5 cancer research centres in the world.

We are incredibly grateful for the impactful gifts made by all of our Till & McCulloch Society members, including the George and Helen Vari Foundation. Their generosity is helping to further cancer research and generate breakthroughs that will revolutionize patient care in Canada and around the world. Thank you all for playing an invaluable role in our vision to Conquer Cancer In Our Lifetime.

From left: George & Helen Vari
From left: Victoria De Luca & Agnes Hilkene

12

If you would like to learn more about joining this elite group of donors, please contact T&MSociety@thepmcf.ca.
Conquering Cancer Together

This year, thousands of passionate supporters came together as a community to raise funds for life-saving cancer research. We extend our heartfelt gratitude to every event participant, volunteer, and donor. Every dollar raised helps The Princess Margaret’s renowned doctors, scientists, and researchers create more revolutionary breakthroughs in cancer research and patient care. Thank you to everyone who came out to support our shared vision—to Conquer Cancer In Our Lifetime.

The Princess Margaret Lottery is Canada’s largest charitable lottery. The program raised over $179 million. These undesignated funds help to fuel life-saving cancer research happening at The Princess Margaret. Ticket purchasers have the opportunity to win incredible real estate prizes, trips, cash, cars, and so much more.

The Ride to Conquer Cancer continues to be Canada’s largest cycling fundraiser, having raised hundreds of millions of dollars for The Princess Margaret since 2008. Every year, thousands of participants gather to cycle over 200 km to support life-saving cancer research. Close to 3,000 participants rode from Toronto to Niagara Falls over the course of two days and raised over $16.7 million.

The Walk to Conquer Cancer continues to be a celebration of hope driven by a community of like-minded people. The annual 21 km half-marathon challenge is one of our longest-running events, and has seen over 20 years of fundraising success. Over 1,400 individuals came together and raised $3.2 million by walking through downtown Toronto.

Road Hockey to Conquer Cancer, fuelled by Longo’s, has raised $27 million over the course of the past 11 years. The combination of energy, excitement, teamwork and sportsmanship make this an incredibly fun and meaningful event that continues to drive life-saving cancer research year after year. Over 1,500 participants, rookies, veterans, sports celebrities and NHL heroes came together to raise over $2.8 million.

Journey to Conquer Cancer is a fun-filled family favourite event where participants can walk or run 1K, 3K, or 5K at their own pace. The community continues to make a meaningful difference in the lives of cancer patients at The Princess Margaret and around the world. To date, we’ve raised over $14 million for life-saving cancer research.

With D.I.Y. to Conquer Cancer you can support innovative cancer research by creating your own personal fundraiser. From craft sales and cooking, to hosting your own event and creating a fundraising page in honour of a loved one, your ideas make a difference.

Quest to Conquer Cancer is a year-long fundraiser where gamers, streamers and content creators from around the world unite to support The Princess Margaret. This event continues to rally the global gaming community together. Participants host charity streams and put their passion for conquering games towards Conquering Cancer. Over the past three years, our worldwide community has raised over $1.2 million for The Princess Margaret.

Northern Pass to Conquer Cancer continues to be Muskoka’s premiere cycling and fundraising event. Since 2017, this unique ride through cottage country has raised millions of dollars for The Princess Margaret. Every year, participants gather to cycle hundreds of kilometres through scenic Muskoka in support of the cause. 250 participants rode through three challenging routes and raised over $720,000 for The Princess Margaret.

Our Events
Tim Hockey and Les Domestiques take their support for the Ride to new heights.

Historic $2.9 Million Raised for Cancer Research

It’s not just a hospital...it’s a cancer research centre, which means everybody in the world benefits from whatever breakthroughs happen there.” — Tim Hockey

Fundraising to support cancer research has taken on new meaning for Tim, whose wife Lana received treatment at The Princess Margaret for pancreatic cancer. “Having gone through it very personally, you really get a sense of what an amazing facility the Cancer Centre is,” said Tim.

“It’s the easiest fundraising I’ve ever done because I care about it and because my friends care about supporting me and my wife,” said Tim. “They really stepped up, not just because they wanted to be supportive of us, but because all of them have been touched by cancer. There isn’t a soul on this planet that hasn’t been touched by cancer.”

Tim has witnessed the impact and fundraising power of the Ride and all of The Princess Margaret’s annual events, and he encourages everyone to join. “Starting a team or even going as a solo rider is intimidating. It might be well beyond anything that you’ve physically tried before. And asking people for money is very scary,” said Tim. “But I think what you’ll find is that it can be the most inspiring thing you’ve ever done.”

Thank you to Tim Hockey and Les Domestiques for their commitment to Conquering Cancer In Our Lifetime.
Dan’s Legacy Will Help Save More Lives

Pat and Gerry Sheehan always described their son Dan as having “the world by the tail.” Then, in January of 2001, one week before his 29th birthday, Dan felt a strange sensation down the right side of his body. He went to the emergency room, where a CAT scan and an MRI revealed a devastating diagnosis: an inoperable brain tumour. “His life had been changed forever,” said Pat.

Still in shock from the news, Dan and his family were introduced to The Gerry and Nancy Pencer Brain Tumour Centre at The Princess Margaret. The clinical research team, headed by Dan’s neuro-oncologist, Dr. Warren Mason, Medical Director of the Pencer Centre, is internationally respected and is at the forefront in the search for a cure for this difficult disease.

Dr. Mason then told the family that even with treatment, the cancer would likely come back within five years. “Physically, emotionally and mentally—it was like getting kicked in the stomach by a horse,” recalls Gerry. “It was an upheaval in your whole idea of what the future would hold for your family, and your son.”

Dan began his treatment at The Princess Margaret, which consisted of radiation followed by chemotherapy. “He wanted to live,” said Pat. “He wanted his future and was willing to do whatever the doctors said to do.” Fortunately, Dan went through treatment without too much difficulty or discomfort and was able to continue working with minimal time off. The tumour went into remission, and he went on with his life.

After his last round of chemotherapy, Dan proposed to his girlfriend Heather. In the fall of 2002 they were married, and the following year, they bought a house and soon had two cats. Dan was allowed to drive his beloved Toyota Celica again and, best of all, to play hockey! Life was good again, and Dan was savouring it.

One year later, a routine MRI revealed the tumour had come back. However, despite courses of treatment with two new drugs for brain tumours, it continued to grow. Early in the morning of July 13, 2005, Dan died peacefully at home with his beloved Heather by his side. He was just 33 years old.

There have been few major advances in the treatment of brain tumours in the past 30 years, but several promising new avenues are starting to appear. Dr. Mason is highly involved in a number of these research projects. “We know that research is all that’s going to get us anywhere with this. We’re not super wealthy, but we’re going to do what we can to help,” said Pat.

And help they have. So far, the Sheehans have raised an impressive $265,000 in support of the work of Dr. Mason and his research team. They’re also leaving a legacy gift in Dan’s honour, making them proud members of The Princess Margaret Cancer Foundation’s J.C.B. Grant Society, which was formed to thank special donors who’ve made Conquering Cancer part of their legacy.

“He’s our son—we just want him to be remembered, and this is one way to do it,” said Pat.

“You try to put your resources where it’s going to do the most good and The Princess Margaret’s reputation is stellar,” said Gerry. “They’re at the forefront of cancer research, and if anyone is going to find a breakthrough, they’ll be the ones to do it.”

Dan’s family will always remember his shining personality, his great sense of humour, and his ability to befriend anyone. And although they will never stop missing him, they’re able to take solace in the fact that his legacy continues to help others. “It comforts us to think that we may be having some small part in sparing other patients and families the pain that we and Dan went through,” said Gerry.

The Princess Margaret researchers are at the forefront of cancer research, and if anyone is going to find a breakthrough, they’ll be the ones to do it.” —Gerry Sheehan

For more information or to tell us you’ve made a gift in your Will, please contact: legacy@thepmcf.ca or call 416.660.1276
Board of Directors

Richard Rooney
Board Chair
Vice Chair and Co-Founder, Burgundy Asset Management Ltd.

Jochen Tilk
Board Vice Chair
Corporate Director

Mark Allison
Vice-President Real Estate, Performance Auto Group

Rohit Bhapkar
Senior Partner, McKinsey & Company

Sarah Bull
Partner and Portfolio Manager, KJ Harrison Investors

Nancy Carroll
Partner & Co-Head, National Insurance and Reinsurance Practice, McCarthy Tetrault LLP

Greg Cochrane*
Managing Partner, VRG Capital

J-F Courville
President and Chief Client Officer, Purpose Unlimited

Bob Dorrance
Chairman, TD Securities

David Engel*
Chief Innovation Officer and CEO, Innovative

Mary Filippelli
Corporate Director

Harry Goldgut
Vice Chair, Infrastructure and Renewable Power & Transition, Brookfield Asset Management Inc.

Reetu Gupta
Ambassador and Principal, The Gupta Group

Helen Mallory Hicks
Corporate Director

Candace Innes
Marketing Consultant

Judith Irving
Philanthropist

Christina Kramer
Senior Executive Vice-Preside and Group Head, Technology Infrastructure and Innovation, CIBC

Stacey Madge
President and Country Manager, Visa Canada

David McGraw
Corporate Director

Eric Monteiro
Senior Vice-President, Group Retirement Services, Sun Life Financial

Dr. Aaron Schimmer
Research Director, Princess Margaret Cancer Centre

Duncan Sinclair
Chair, Deloitte Canada and Chile

Dr. Kevin Smith
President and Chief Executive Officer, University Health Network

Dr. Keith Stewart
Vice President, Cancer and Director, Princess Margaret Cancer Program

Sean St. John
Executive Vice-President, Managing Director and Head of Fixed Income, and Co-Head of Risk Management Solutions, National Bank Financial Markets

Humza Teherany
Chief Technology and Digital Officer, Maple Leaf Sports & Entertainment

Stuart Waugh
Managing Director and Managing Partner, NorthWest Capital Partners

Dr. Bradley Wouters
Executive Vice-President, Science and Research, University Health Network

Donna E. Young
Founding Dean, School of Law, Toronto Metropolitan University

Our thanks are extended to the following individuals from our community of supporters who serve on committees of The Princess Margaret Cancer Foundation:

Terry Bacchelli
Anish Chopra
Tom Ehrlich
Omeonga Saidi
Maureen Shaugnessy Kitts
Tina Tehranchian
Michael Wilson
Aazar Zafar

*Board term began at September 2022 Annual General Meeting
Board of Trustees

University Health Network (UHN)  April 1, 2022 to March 31, 2023

Elected Trustees (Voting)

Brian Porter
Chair
Former President and Chief Executive Officer, Scotiabank

Ross Baker
Professor, Institute of Health Policy, Management and Evaluation, University of Toronto

Dean Connor
Former President and Chief Executive Officer, Sun Life Financial

Janice Fukakusa
Chancellor, Toronto Metropolitan University

Todd Halpern
President, Halpern Enterprises

Stu Kedwell
Senior Vice-President and Senior Portfolio Manager, Co-Head North American Equities, RBC Global Asset Management

Peter Menkes
President, Commercial/Industrial Division, Menkes Developments Ltd.

Janet Rossant
Senior Scientist, SickKids
Professor, University of Toronto

Shirle Sharkey
Board Director and Advisor; Former Chief Executive Officer, SE Health

Ajay Virmani
President and Chief Executive Officer, Cargill

Lawrence Pentland
Former Executive, Dell Inc.

Peter Wallace
Former Secretary of the Treasury Board, Government of Canada

Jaime Watt
Executive Chairman, Navigator

Pamela Warren
Partner, Egon Zehnder

Cornell Wright
President, Wittington Investments, Limited

Ex Officio Trustees (Non-Voting)

Dr. Kevin Smith
President and Chief Executive Officer, University Health Network

Pamela Hubley
Chief Nursing Executive, University Health Network

Sheryl Seidman
President, Medical Staff Association, University Health Network

Richard Rooney
Board Chair, The Princess Margaret Cancer Foundation Board of Directors

Patricia Murphy
Chair, Medical Advisory Committee, University Health Network

Raj Kothari
Chair, University Health Network Foundation Board of Directors

Principal, Centre Street Enterprises

Trustees Appointed by U of T Governing Council (Voting)

Cheryl Regehr
Vice-President and Provost, University of Toronto

Trevor Young
Dean, Faculty of Medicine and Vice-Provost, Relations with Health Care Institutions, University of Toronto

Trevor Young
Dean, Faculty of Medicine and Vice-Provost, Relations with Health Care Institutions, University of Toronto
Chairs

A Chair is the highest honour in academic life, prestigious for Chairholder and donor alike. Our Chairholders are recognized internationally for superior academic achievement, experience and success in teaching and research.

Princess Margaret Cancer Centre April 1, 2022 to March 31, 2023

Held Chairs

AMGEN Chair in Cancer Research
Dr. Robert Rottapel

Bartley-Smith Wharton Chair in Radiation Oncology
Dr. John Waldron

Daniel E. Bergsagel Chair in Medical Oncology
Dr. Amit M. Oza

Molly and David Bloom Chair in Multiple Myeloma Research
Dr. Donna Rege

BMO Financial Group Chair in Precision Genomics
Dr. Lillian Siu

Alan B. Brown Chair in Molecular Genomics
Dr. Geoffrey Liu

Ronald N. Burt Chair in Oncology Research
Dr. Aaron Schimmer

Bartley-Smith Wharton Chair in Radiation Oncology
Dr. Jennifer Jones

M. Qasim Choksi Chair in Lung Cancer Translational Research
Dr. Ming S. Tsao

Richard H. Clark Chair in Cancer Medicine
Dr. Keith Steward

J. Douglas Craster Chair in Gynecologic Cancer Research
Dr. Sarah Ferguson

Helga and Antonio De Gasperis Chair in Blood Cancer Stem Cell Research
Dr. John Dick

Dr. Mariano Antonio Elia Chair in Head and Neck Cancer Research
Dr. Scott Brahman

Anna-Lisa Fargharian Chair in Kidney Cancer Research
Dr. Antonio Pinelli

Gray and Mary Fidani Family Chair in Radiation Physics
Dr. Jan Seuntjens

Gattuso Chair in Breast Surgical Oncology
Dr. Tulin Gil

Peter and Sheltagh Godose Chair in Radiation Medicine
Dr. Fei Fei Liu

J.C.B. Grant Chair in Oncologic Pathology
Dr. George Yousef

Gulane Family/O’Neil Family Chair in Otolaryngology/Head and Neck Surgery
Dr. Ralph W. Gilbert

K. Y. Ho Chair in Prostate Cancer Research
To be appointed

Kirchmann Family Chair in Neuro-Oncology Research
Dr. Warren Mason

Lee K. and Margaret Lau Chair in Breast Cancer Research
Dr. Razqullah Hakem

Harold and Shirley Lederman Chair in Psychosocial Oncology and Palliative Care
Dr. Camilla Zimmermann

Wilfred G. LeWitt Chair in Pancreatic Cancer Research
Dr. Jennifer J. Knox

The Love Chair in Prostate Cancer Prevention Research
Dr. Neil Fleshner

The Addie MacNaughton Chair in Thoracic Radiation Oncology
Dr. Alexander Sun

Chair in Medical Imaging and Artificial Intelligence
Dr. Christopher McIntosh

Philip S. Oroso Chair in Leukemia Research
To be appointed

OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development
Dr. Natasha B. Leighl

RBC Chair in Nursing Oncology, Research and Education
Dr. Samantha Mayo

Kevin and Sandra Sullivan Chair in Surgical Oncology
Dr. Jonathan C. Irish

Joey and Toby Tanenbaum/Brazilian Ball Chair in Prostate Cancer Research
Dr. Housheng He

Trachtenberg/Haque Chair in Image Guided Prostate Therapy Research
Dr. Sangareet Ghai

Weekend to End Breast Cancer Chair in Breast Cancer Research
Dr. Arthi Jeyaraj

Westaway Chair in Ovarian Cancer Research
Dr. Stéphanie Lheureux

The Robert E. Wharton Chair in Head and Neck Surgery
Dr. David Goldstein

The Robert E. Wharton Chair in Reconstructive Plastic Surgery
Dr. Stefan O. Hofler

AMGEN Chair in Cancer Research
Dr. Robert Rottapel

Bartley-Smith Wharton Chair in Radiation Oncology
Dr. John Waldron

Daniel E. Bergsagel Chair in Medical Oncology
Dr. Amit M. Oza

Molly and David Bloom Chair in Multiple Myeloma Research
Dr. Donna Rege

BMO Financial Group Chair in Precision Genomics
Dr. Lillian Siu

Alan B. Brown Chair in Molecular Genomics
Dr. Geoffrey Liu

Ronald N. Burt Chair in Oncology Research
Dr. Aaron Schimmer

Bartley-Smith Wharton Chair in Radiation Oncology
Dr. Jennifer Jones

M. Qasim Choksi Chair in Lung Cancer Translational Research
Dr. Ming S. Tsao

Richard H. Clark Chair in Cancer Medicine
Dr. Keith Steward

J. Douglas Craster Chair in Gynecologic Cancer Research
Dr. Sarah Ferguson

Helga and Antonio De Gasperis Chair in Blood Cancer Stem Cell Research
Dr. John Dick

Dr. Mariano Antonio Elia Chair in Head and Neck Cancer Research
Dr. Scott Brahman

Anna-Lisa Fargharian Chair in Kidney Cancer Research
Dr. Antonio Pinelli

Gray and Mary Fidani Family Chair in Radiation Physics
Dr. Jan Seuntjens

Gattuso Chair in Breast Surgical Oncology
Dr. Tulin Gil

Peter and Sheltagh Godose Chair in Radiation Medicine
Dr. Fei Fei Liu

J.C.B. Grant Chair in Oncologic Pathology
Dr. George Yousef

Gulane Family/O’Neil Family Chair in Otolaryngology/Head and Neck Surgery
Dr. Ralph W. Gilbert

K. Y. Ho Chair in Prostate Cancer Research
To be appointed

Kirchmann Family Chair in Neuro-Oncology Research
Dr. Warren Mason

Lee K. and Margaret Lau Chair in Breast Cancer Research
Dr. Razqullah Hakem

Harold and Shirley Lederman Chair in Psychosocial Oncology and Palliative Care
Dr. Camilla Zimmermann

Wilfred G. LeWitt Chair in Pancreatic Cancer Research
Dr. Jennifer J. Knox

The Love Chair in Prostate Cancer Prevention Research
Dr. Neil Fleshner

The Addie MacNaughton Chair in Thoracic Radiation Oncology
Dr. Alexander Sun

Chair in Medical Imaging and Artificial Intelligence
Dr. Christopher McIntosh

Philip S. Oroso Chair in Leukemia Research
To be appointed

OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development
Dr. Natasha B. Leighl

RBC Chair in Nursing Oncology, Research and Education
Dr. Samantha Mayo

Kevin and Sandra Sullivan Chair in Surgical Oncology
Dr. Jonathan C. Irish

Joey and Toby Tanenbaum/Brazilian Ball Chair in Prostate Cancer Research
Dr. Housheng He

Trachtenberg/Haque Chair in Image Guided Prostate Therapy Research
Dr. Sangareet Ghai

Weekend to End Breast Cancer Chair in Breast Cancer Research
Dr. Arthi Jeyaraj

Westaway Chair in Ovarian Cancer Research
Dr. Stéphanie Lheureux

The Robert E. Wharton Chair in Head and Neck Surgery
Dr. David Goldstein

The Robert E. Wharton Chair in Reconstructive Plastic Surgery
Dr. Stefan O. Hofler

University Health Network April 1, 2022 to March 31, 2023

Joint Chairs

Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation
Dr. Jonas Mattson

Fleck/Tanenbaum Chair in Prostatic Diseases
To be appointed

The Alan and Susan Hudson Chair in Neuro-Oncology
Dr. Andres Lozano

Pearson/Ginsberg Chair in Thoracic Surgical Oncology
Dr. Kazuhiro Yasufuku

Scotiabank Research Chair
Dr. David Brooks

J. Gerald Scott/David G. Whitmore Chair in Hematology and Gene Therapy Research
To be appointed

Scott Taylor Chair in Lung Cancer Research
Dr. Frances A. Shepherd

A sincere thank you to our donors who fund these prestigious positions.
Financial Summaries

5-Year Overview

Each year, The Princess Margaret Cancer Foundation reports on the funds it raises and stewards in two ways: via Audited Financial Statements (AFS), online at www.thepmcf.ca and via the standard CRA T3010 form required of all not-for-profit organizations and found on the CRA website at www.canada.ca/en/services/taxes/charities.html. While both formats utilize the same financial information, the Foundation’s AFS provides a more detailed look to better assess and control our financial performance.

Statement of Revenue, Expenses and Changes in Fund Balances ($ thousands)

<table>
<thead>
<tr>
<th>Year Endered March 31</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross Fundraising Revenue</td>
<td>91,822</td>
<td>122,861</td>
<td>85,898</td>
<td>91,531</td>
<td>104,920</td>
</tr>
<tr>
<td>Direct Fundraising Expenses</td>
<td>21,998</td>
<td>24,434</td>
<td>15,858</td>
<td>22,169</td>
<td>29,354</td>
</tr>
<tr>
<td>Net Fundraising</td>
<td>69,824</td>
<td>98,427</td>
<td>70,039</td>
<td>69,362</td>
<td>75,566</td>
</tr>
<tr>
<td>Gross Lottery Revenue</td>
<td>88,239</td>
<td>102,904</td>
<td>113,170</td>
<td>191,259</td>
<td>179,963</td>
</tr>
<tr>
<td>Direct Lottery Expenses</td>
<td>64,627</td>
<td>69,422</td>
<td>66,772</td>
<td>99,600</td>
<td>107,334</td>
</tr>
<tr>
<td>Net Lottery</td>
<td>33,612</td>
<td>41,482</td>
<td>46,398</td>
<td>91,659</td>
<td>72,629</td>
</tr>
<tr>
<td>Net Fundraising and Lottery Revenue</td>
<td>103,436</td>
<td>140,009</td>
<td>116,437</td>
<td>161,021</td>
<td>148,195</td>
</tr>
<tr>
<td>Investment Income (Loss)</td>
<td>36,964</td>
<td>5,153</td>
<td>114,444</td>
<td>37,140</td>
<td>16,453</td>
</tr>
<tr>
<td>Net Revenue, including Investment Income</td>
<td>140,400</td>
<td>135,856</td>
<td>230,881</td>
<td>198,161</td>
<td>164,648</td>
</tr>
<tr>
<td>General Fundraising and Administrative Expenses</td>
<td>9,603</td>
<td>9,743</td>
<td>10,886</td>
<td>7,735</td>
<td>9,282</td>
</tr>
<tr>
<td>Excess of Revenue over Expenses before Grants</td>
<td>130,797</td>
<td>125,113</td>
<td>219,995</td>
<td>190,426</td>
<td>155,366</td>
</tr>
<tr>
<td>Grants to Princess Margaret Cancer Centre</td>
<td>(9,635)</td>
<td>(8,661)</td>
<td>(16,709)</td>
<td>(4,676)</td>
<td>(13,076)</td>
</tr>
<tr>
<td>Research, Education and Patient Care</td>
<td>(93,169)</td>
<td>(82,998)</td>
<td>(92,587)</td>
<td>(106,133)</td>
<td>(127,546)</td>
</tr>
<tr>
<td>Equipment</td>
<td>(1,868)</td>
<td>(4,122)</td>
<td>(3,741)</td>
<td>(3,214)</td>
<td>(4,265)</td>
</tr>
<tr>
<td>Total Grants to Princess Margaret Cancer Centre</td>
<td>(104,672)</td>
<td>(105,781)</td>
<td>(113,037)</td>
<td>(114,023)</td>
<td>(144,882)</td>
</tr>
<tr>
<td>Excess of Revenue over Expenses and Grants for the Year</td>
<td>26,125</td>
<td>19,332</td>
<td>106,956</td>
<td>76,403</td>
<td>10,484</td>
</tr>
<tr>
<td>Fund Balances</td>
<td>294,553</td>
<td>271,702</td>
<td>362,660</td>
<td>394,551</td>
<td>377,728</td>
</tr>
<tr>
<td>Endowments</td>
<td>276,906</td>
<td>325,210</td>
<td>333,390</td>
<td>383,128</td>
<td>400,836</td>
</tr>
<tr>
<td>Restricted</td>
<td>16,506</td>
<td>19,332</td>
<td>106,956</td>
<td>76,403</td>
<td>10,484</td>
</tr>
<tr>
<td>Total Fund Balances</td>
<td>587,995</td>
<td>607,327</td>
<td>714,285</td>
<td>790,688</td>
<td>801,172</td>
</tr>
<tr>
<td>Held by University of Toronto (as of April 30)</td>
<td>603,819</td>
<td>622,483</td>
<td>732,469</td>
<td>808,740</td>
<td>819,302</td>
</tr>
</tbody>
</table>

Fiscal 2023

The Princess Margaret Cancer Foundation is passionate about impact, efficient fundraising and effective stewardship to ensure that we can achieve our collective vision to Conquer Cancer In Our Lifetime.

Fulfilling Our Mission

Our mission is to raise and steward funds to deliver breakthrough research, exemplary teaching, and compassionate care at Princess Margaret Cancer Centre, one of the top 5 cancer research centres in the world. Beyond funds granted this year ($144.9 million), the Foundation has multi-year research and clinical commitments in progress at the Cancer Centre.

Based on reported net fundraising revenue and lottery revenue ($148.2 million):

- **Lotteries**: 49.0%
- **Major Gifts and Bequests**: 36.7%
- **Annual Programs**: 13.2%
- **Other**: 1.1%

Grants provided to the Princess Margaret Cancer Centre ($144.9 million):

- **Research, Education, Patient Care**: 88.1%
- **Building**: 9.0%
- **Equipment**: 2.9%

**Year-Over-Year Highlights**

Net fundraising and lottery revenue ($ millions)

<table>
<thead>
<tr>
<th>Year</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Revenue</td>
<td>$103.4 million</td>
<td>$140.0 million</td>
<td>$116.4 million</td>
<td>$161.0 million</td>
<td>$148.2 million</td>
</tr>
<tr>
<td>Lottery Prizes</td>
<td>28.0%</td>
<td>72.0%</td>
<td>$29.3 million</td>
<td>$75.6 million</td>
<td>$40.3 million</td>
</tr>
<tr>
<td>Marketing &amp; Other Expenses</td>
<td>37.3%</td>
<td>22.3%</td>
<td>$67.1 million</td>
<td>$40.3 million</td>
<td>$72.6 million</td>
</tr>
<tr>
<td>Net Lottery Revenue</td>
<td>37.3%</td>
<td>22.3%</td>
<td>$67.1 million</td>
<td>$40.3 million</td>
<td>$72.6 million</td>
</tr>
</tbody>
</table>

The PMCF net return of 40.4% compares favourably to the industry average return of 36.6% based on the top charitable lotteries in Ontario.

Fiscal Efficiency Measure

The PMCF raised $1.39 million per full-time employee, making it one of the most efficient and effective charities in Canada.

Financials

- **Per Full-Time Employee**: $1.39 million
- **Net Revenue Raised**: $148.2 million
How The Princess Margaret Helped Allen Beat the Odds

As a two-time survivor and the author of On the Other Side of TERMINAL, Allen is not one to shy away from talking about cancer.

When he was younger, he knew of its power and strength, but Allen never thought he would come to know the disease so intimately. “I assumed that I would be one of the lucky ones to never personally get to know such an illness,” he said. “I was wrong.”

At the age of 21, Allen was diagnosed with Hodgkin’s disease. Thankfully, the cancer went into remission and Allen continued to live a fulfilling life. But 25 years later, Allen received life-changing news again: he had Stage 4 salivary duct carcinoma.

With no known cure, treatment options for the aggressive and rare form of head and neck cancer were limited. “My kids were 9 and 12 at the time I was diagnosed, and it was heartbreaking,” said Allen. “[But] it was a breath of fresh air knowing that I was in the right place at Princess Margaret Cancer Centre.”

After surgery and radiation, scans showed the cancer had spread and was deemed terminal. Allen had to decide whether to begin palliative chemotherapy to control the disease for as long as possible, or find an alternative. Determined despite the bad prognosis, Allen chose the latter. He and his girlfriend Cynthia began reading hundreds of peer-reviewed journal articles, and working closely with his oncologist, Dr. Lillian Siu, to see if they could come up with creative ways to approach treatment.

Genetic sequencing and surgical pathology results revealed androgens—the hormones that contribute to growth and reproduction in both men and women—were the culprit behind the cancer’s growth. The discovery led to a personalized approach to treatment: he began androgen deprivation therapy, a form of prostate cancer treatment.

Miraculously, it worked.

Against all odds, Allen is thriving seven years later. He credits his survival to his entire care team, the loving support from his family, and the determination to reclaim his life from cancer’s grip.

Allen has received care from teams led by Medical Oncologists Dr. Lillian Siu and Dr. Lawson Eng, and Dr. Madeline Li, Co-Lead of the Psychosocial Oncology Clinic at the Department of Supportive Care.

He emphasizes that The Princess Margaret understands the physical and emotional impact of cancer. “Their visionary approach to blending life-saving outcomes and world-class discoveries with emotional support, such as the excellent therapy offered through the Department of Psychosocial Oncology, is a tremendous benefit for the cancer community at large,” said Allen.

Thanks to The Princess Margaret, Allen has been able to attend many milestone moments alongside Cynthia and their children, like graduations and theatre performances, and continues to win backgammon tournaments, a game he’s passionate about. “I’ve always been a big backgammon player—The Princess Margaret said there’s always hope. You stick it out and you keep playing the game. No matter how bad the odds are, there is always a chance. The key is to keep playing the game.”
# Board Committees

**The Princess Margaret Cancer Foundation**

**Board Committees**

<table>
<thead>
<tr>
<th>Board Committee</th>
<th>Leadership</th>
<th>Membership</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Executive Committee</strong></td>
<td>Chair: Richard Rooney</td>
<td>J-F Courville, Harry Goldgut, Stacey Madge, Helen Mallovy Hicks</td>
</tr>
<tr>
<td>Vice Chair: Jochen Tilk</td>
<td></td>
<td>Duncan Sinclair, Sarah Bul, Dr. Kevin Smith (UHN CEO)</td>
</tr>
<tr>
<td><strong>Audit &amp; Risk</strong></td>
<td>Chair: Helen Mallovy Hicks</td>
<td>Christina Kramer, David McGraw, Richard Rooney</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Duncan Sinclair, Richard Rooney, Angela McDonald (Community)</td>
</tr>
<tr>
<td><strong>Commercialization</strong></td>
<td>Chair: J-F Courville</td>
<td>Richard Rooney, Stuart Waugh, Rohit Bhatpuri</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Michael Crackower (Community)</td>
</tr>
<tr>
<td><strong>Ex Officio (Non-Voting):</strong></td>
<td></td>
<td>Dr. Bradley Wouters (UHN VP Research), Dr. Aaron Schimmer (Research Director, PM Cancer Centre)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mark Taylor (UHN), Lawrence Pentland (Chair, UHN Board Research Committee)</td>
</tr>
<tr>
<td><strong>Governance</strong></td>
<td>Chair: Duncan Sinclair</td>
<td>Nancy Carroll, Mary Filipelli, Candace Innes, Richard Rooney</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Donna Young, Maureen Shaughnessy Kitts (Community)</td>
</tr>
<tr>
<td><strong>Granting, Stewardship &amp; Impact</strong></td>
<td>Chair: Harry Goldgut</td>
<td>Judith Irving, Christina Kramer, Richard Rooney</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sean St. John, Humza Tehranany, Jochen Tilk</td>
</tr>
<tr>
<td><strong>Ex Officio (Non-Voting):</strong></td>
<td></td>
<td>Dr. Keith Stewart (VP, Cancer), Dr. Bradley Wouters (UHN, VP Research)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr. Aaron Schimmer (Research Director, PM Cancer Centre)</td>
</tr>
<tr>
<td><strong>Human Resources Committee</strong></td>
<td>Chair: Stacey Madge</td>
<td>Eric Montiero, Richard Rooney</td>
</tr>
<tr>
<td><strong>Investment</strong></td>
<td>Chair: Sarah Bull</td>
<td>Richard Rooney, Bob Dorrance, Stuart Waugh</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anish Chopra (Community), Omeonga Saidi (Community), Aazaz Zafar (Community), Terry Biazordo (Community)</td>
</tr>
<tr>
<td><strong>Fundraising Advisory Board</strong></td>
<td>Chair: Jochen Tilk</td>
<td>Mark Allison, Harry Goldgut, Stacey Madge, Richard Rooney, Duncan Sinclair, Reetu Gupta</td>
</tr>
<tr>
<td></td>
<td></td>
<td>David Engst, Greg Cochrane, Tom Ehrlich (Community), Tina Tehranchian (Community), Michael Wilson (Community)</td>
</tr>
</tbody>
</table>

**Business Committees with Board membership**

<table>
<thead>
<tr>
<th>Board Committee</th>
<th>Leadership</th>
<th>Membership</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marketing Advisory</td>
<td>Chair: Melanie Johnston</td>
<td>Stacey Madge, Candace Innes, Eva Salem (Community)</td>
</tr>
<tr>
<td>Lottery</td>
<td>Chair: Ramona Oss</td>
<td>Richard Rooney, Helen Mallovy Hicks, David McGraw</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mark Allison, Candace Innes, Maureen Shaughnessy Kitts (Community)</td>
</tr>
</tbody>
</table>

**UHN Governance Appointments**

<table>
<thead>
<tr>
<th>Committee</th>
<th>Role</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>UHN Board of Trustees</td>
<td>Board Chair</td>
<td>Richard Rooney</td>
</tr>
<tr>
<td>UHN Finance &amp; Audit Committee</td>
<td>Treasurer</td>
<td>Helen Mallovy Hicks</td>
</tr>
<tr>
<td>UHN Research Committee</td>
<td>Chair, Granting, Stewardship &amp; Impact</td>
<td>Harry Goldgut</td>
</tr>
</tbody>
</table>
Our Donors

Thank you to all of our supporters who have given so generously. Contributions reflect lifetime giving from $25,000 and above.
Thank you all to our supporters who have given so generously. Contributions reflect lifelong giving from $25,000 and above.

**Champion**

- The Lassen - Del Guardian Charitable Fund
- Richard and LaVerde Lederman and Family
- The LeDonner Family Foundation
- The Lillian Myhren and Don Wright Foundation
- Linda and Hewat Siddalowski Charitable Foundation
- Eric MacFarish
- MacFarlane Group Foundation Ltd.
- The Madsen-Venn Mitchell and Grace Venn-Mitchell Cancer Research Fund
- Marjorie Allan Fern Foundation
- Master Insulators’ Association of Ontario Inc.
- S. Scott McCain
- Martha LA McCain
- McCarthy Tetrahedron Foundation
- Mervin McLellan Canada Inc.
- Wanda Mironis
- Municipality of Metro Toronto
- W. Patrick J. Neal and Deanna I. Neal
- Next Plumbing & Hydronics Supply Inc.
- Norm and Laura Lamarche Family Foundation
- Rhonda and Mel Pearl
- Wanda Mikonis
- Martha LA McCain
- J. Scott McCain
- Master Insulators’ Association of Ontario Inc.
- The Eaton Foundation
- E.W. Bickle Foundation
- Dylex Limited
- Eric and Heather Donnelly
- Ian and Anne Devine
- Domenic and Bernisea Dell’Elce
- Anne Margaret Delicaet
- John Davison
- Credit Suisse and the Credit Suisse Americas Foundation
- Eve and Harold Corrigan
- Barry and Sue Cooper
- Esther and Jack Cole and Family
- Steven Cohen
- Georg Wilton and Jeanne Poulin
- Florence and Mickey Wintberg
- John O’Connor
- Geoffrey Allan Boyes
- Marsha Bielak and Family
- Thomas J. and Sonja Bata
- C.W. Barootes
- A. Charles Baillie
- Mark and May Allison
- Clive and Barbara Allen
- James Grant LeBlanc
- Joyce E. Larkin
- Jamie and Leah Bras and Family
- The Chrysler Canada Fund
- The Banting Fund
- Canada’s Best Barns
- The Lillian Meighen and Don Wright Foundation
- The LeGresley Family Foundation
- The Larsen - Del Guidice Charitable Fund
- The Leukemia and Lymphoma Society of Canada
- The Grand Chapter of Royal Arch Masons of Canada
- Senator Jerry and Carole Grafstein
- Gail H. Koff and Carol Koff Foundation
- George Kalmar and Family
- In Honour of Florence Bull Karson
- Katz Group Canada Ltd.
- Judith and Stephen Kaufman
- Kathy and Jess Kaplan
- Toronto Firefighters Association
- The Guelph Container Corporation
- Ralph Zarboni
- Lawrence William Wert
- We Love You Connie Foundation-Guglietti Family
- Douglas Thompson
- Zeus Securities Inc.
- Adam and Sarah Frank
- We Love You Connie Foundation-Guglietti Family
- Geoffrey and Dawn Ogram
- Chris G. Paliare and Eva Marszewski
- Jim Mourgelas
- Karen and Paul Morton
- Helen Stark
- Terese and Allan Weisberg
- George and Diane Stainton
- William and Emily Small
- Daniel R. Stone
- Carol Thatcher
- Karen Weil
- John William Store
- Super Gas and Service Ltd.
- Thailand First Energy
- Bill Swainson
- Monica Topp
- Marcel Thirion
- Mark and Shannon Thomas
- Pearson
drivendesign
- The Pickle Barrel
- Thomas William Walker
- Walmart Canada Corp.
- United Association of Plumber and Fitter Local 46
- The Phillips Foundation
- The Pilar Foundation
- John Labatt Limited
- Sherry and Susan Wengard
- Linda and Jerry Wengard
- Paul and Kim Yeo
- The Woodford Foundation
- Cookies for Kids’ Cancer
- Brookfield Partners Foundation
- The Schneider Family Foundation
- Sears Canada Employees Charitable Fund
- Russia
- Philip Rubino
- Aveo and Fondi Rotta
- Ford
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
- Singapore Investors League
Our Donors

Thank you to all of our supporters who have given so generously. Contributions reflect lifetime giving from $25,000 and above.
Thank you to all of our supporters who have given so generously. Contributions reflect lifetime giving from 1960 to 2019.
Thank you to all of our supporters who have given from $25,000 and above. Contributions reflect lifetime giving from $25,000 and above.
Thank you to all of our supporters who have given so generously. Contributions reflect lifetime giving from $25,000 and above.
Our Donors

Thank you to all of our supporters who have given so generously.
Contributions reflect lifetime giving from $25,000 and above.
Thank you to all our contributors who have given us $25,000 and above. Contributions reflect lifetime giving from $25,000 and above.
Thank you to all of our supporters who have given so generously. Contributions reflect lifetime giving from $25,000 and above.
We are deeply grateful to society members for making The Princess Margaret a part of their legacy.

**J.C.B. Grant Society**

- Richard Cadieux
- Laura Byl
- Graziella Bushe
- Reta Burrows
- Ruth M. Buchanan
- Beverley A. Briggs
- Harold and Fredelle Brief
- Cindy Breslin-Carere and George Carere
- John and Susan Bowey
- Robindra N. Bose
- Frank Bosco
- Sandra (Sandy) Bolyki
- Michel C. Bois
- Nicholas and Zachary Blease-Trepanier
- Katherine Barilla
- Jack and Patricia Barclay
- William F. Badke
- Chuck Arrigo
- Shirley Arnold
- Keith Ambachtsheer and Virginia Atkin
- Paul and Sheila Alofs
- Nicolas Alipheris
- Bruce Alexandor
- Scarlat Albright
- Frances I. Masefield Acheson
- Madeline Fielding
- Timen P. Ho and Ling H. Ho-Lai
- David and Louise Hilson
- Joan R. Hickey
- Grant Hern
- David Hedley
- Suzanne Hearn
- Lenard Haywood
- Sharyl Haynes
- Helen Phebe Hatton
- Kevin Harper and Victoria Clare
- Doris Haslock
- Anne Clements
- Jacques and Jordan Cobb Martin
- Anne Clements
- Julie Colosimo
- Julie Colosimo
- Jaudon and Jasper Cobb Martin
- Anne Clements
- Valerie and James Darroch
- Margaret Corey
- Andrew Colwell and Richard Ellis
- Mary Dawkins
- Jean Davison
- Julie Davis
- Aspasia Dassios
- Barry Crookes
- Elizabeth Carlier
- Sandra Bolyki
- Michel C. Bois
- Nicholas and Zachary Brene-Trepanier
- Michel C. Bois
- Candace Bodas-Bolyki
- Frank Bosco
- Roberta N. Bose
- John and Susan Brewley
- Cindy Breznin-Careen and George Careen
- Harold and Frederle Brief
- Beverly A. Bingo
- Rob Brubos
- Lois C. Brown and Dan Brown
- William P. Gill and Billy Brown
- Ruth M. Buchanan
- Geraldine Guest
- Richard Cadieux
<table>
<thead>
<tr>
<th>Expendable Funds</th>
<th>Endowed Funds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Edward Fulderman Leukemia Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Eleanor and Burnett Thai Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Elizabeth Duke Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Elizabeth M. Francis Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Elina Pearl Finder Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>End Hildebrand Cancer Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Ernest A. and Evelyn C. Byworth Trust for Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>The Everett Family Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Fielding Family Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Florence Winberg Breast Cancer Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Fresa Ariela Muscariwitch ovarian Cancer Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Fritz Spies Research Award</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Gail Eisen Pediatric Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>George and Kathleen Vice Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>George Knouf Memorial Fellowship Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Gerald and Sheila Hatch Fellowship Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>The Gerald Kirsh Humanitarian Award Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Gerry and Nancy Nancy Centre Endowment Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Gibson Clinical Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Girling/MacLean Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Glydi M. Jaziz Potent Services Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Glenn and Marilyn Hunnings Fund in Haemopoietis/Lymphopoietis Research</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Guthrie Family Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Guenstfeld H. Riding Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Harry Usher and Cindy Armstrong Multiple Myeloma Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Harold E. Johns Research Prize Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Harold E. Johns Research Prize Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Harry and Donovan W.L. Rickett Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>The Harry and Joyce Gibbard Cancer Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>The Head &amp; Neck Cancer Radiation Fellowship Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Helen M. Cooke Prostate Cancer Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Helen V. Crawford Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Helena Lam Fellowship in Cancer Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>The Hibiscus Fund for Hope</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Honourable Willard Z. Estey Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Hubert B. Grants Ovarian Cancer Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for Ocular Oncology</td>
<td>Ian Tannock Fellowship Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Jane and Peter Eby Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Ian Tannock Fellowship Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Herbert E. Yeo Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Herbert E. Yeo Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Herbert E. Yeo Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Herbert E. Yeo Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Herbert E. Yeo Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Herbert E. Yeo Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Herbert E. Yeo Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Herbert E. Yeo Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Herbert E. Yeo Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Herbert E. Yeo Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Herbert E. Yeo Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Herbert E. Yeo Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Herbert E. Yeo Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Herbert E. Yeo Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Herbert E. Yeo Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Herbert E. Yeo Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Herbert E. Yeo Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Herbert E. Yeo Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Herbert E. Yeo Research Fund</td>
</tr>
<tr>
<td>Paul Finger Fund for International Fellowships in Ocular Oncology</td>
<td>Herbert E. Yeo Research Fund</td>
</tr>
</tbody>
</table>
Endowed Funds

John and Esther Loewen Family Fund
John L. Hockey Endowment Fund
John Funkus Fund for Lung Cancer Research
Joseph Lorre Garvin Research Fund
Joseph Robert Russell Research Fund
Junior League of Toronto Pediatric Radiation Fund
Katharine S. McCleod Research Fund
Kushnend Sarjana Multiple Myeloma Research Fund
Lee K. and Margaret Lau Breast Cancer Research Fund
Leslie Zev Zipes Fund
Lyndsay, Joey and Sam Lyons Fund
Lynn King Palliative Care Fund
M. Ann MacMan Research Fund
Margaret Mary Victor Endowment Fund
Margaret Pollock Research Fund
Marion H. McRoberts Research Fund
Mary C. Conway Research Fund
The Mary and Sarah MacGill Cancer Research Fund
Mary Pawling Fund for Research into Lung Cancer
The Mary Susan MacDonald Stomach Cancer Research Fund
Max Tennaborn Music Program Fund
McDowell-Glask Family Research Fund
Melissa Ann Katzin Cancer Research Fund
Michael Karim Hart Adolescent and Young Adult Program Fund
Michael X. and Wanda Paichita Fellowship Fund
Milford Early Research Fund
Mildred Goldberg Fellowship Fund
Mindy Krikel Bridge to the Cure Endowment Fund
Monica Wright Roberts National Breast Cancer Endowment Fund
Morris and Marja Hanlon Fund
Montgomery-Copping Palliative Care Endowment Fund
N. B. Kreed Fellowship in Translational Research Fund
Nizar and Gubrin Karni Fund
Norman Latoszynski Leukemia Fund
Oberlander Fellowship in Lung Cancer Research
Pak Heng Chu Research Fund
Paola Colozza Fund for Drug Discovery
Pearl Baines Family Endowment in Melanoma Research and Patient Care Fund
Percher Centre Patient and Family Advisory Committee Fund
Philip and Terry Brown Keegan Cancer Research Fund
Philip Lempert Life Over Lymphoma Endowment Fund
Philip Tanno Cancer Research Endowment Fund
Philippa Harris Annual Lecture Fund
Phyllis Hanzlo Breast Cancer Fund
Phyllis Smith Nursing Education Fund
The Rabbi Joseph and Doris Kanner Fund
Reid-White Family Leukemia Research Fund
Richard H. Grimm Lectureship in Head & Neck Oncology Fund
Robert G. Matthews Cancer Research and Education Fund
Robert Usavage Bone Marrow Transplant Fund
Roy Arthur Fawcett Cancer Research Fund
Ryder MacDougall Family Fund
Shawn’s Miracle Fund
Shnur Bagi Memorial Fund for Basic Research in Ovarian Cancer
Shirley Maie Breast Cancer Research Fund
Spooner Family Endowment Fund
Steven Hoffman Fellowship in Molarc Geriatrics Fund
Stevens/Peters/Doyle Fellowship in Radiation Medicine Fund
Structural Biology and Cell Signaling Fund
Susan E. Creer Ovarian Cancer Early Detection Fund
Sylvia and Louis Lackman Patient Education Program Fund
Sylvia and Jaspal Pancreatic Cancer Research Fund
TD Fund for Medical Discovery
Teddy Orenstein Research Fund
Tetra Boman Shroff Fund in Multiple Myeloma Research
Terry Watson Research Fund
Tony Punnellas Fund
Val Trigus Sarcoma Research Fund
Valerie Dickson Fund
Vera McDermott Patient Education Fund
W. J. Collins and J. A. McIsaac Research Fund
Walter B. Pape Fund
Wharton Lectureship in Head and Neck Cancer Fund
William and Dorothy Dvingay and Family Ovarian Cancer Research Fund

The Princess Margaret UHN

Office/Courier Address
700 University Avenue, 4th Floor, Toronto, ON M5G 1Z5
T 416.946.6500 / 1.866.224.6500
F 416.946.6563

Mailing Address
610 University Avenue, Toronto, ON M5G 2M9

Charitable Organization No. 88900 7597 RR0001

To learn how you can help conquer cancer visit thepmcf.ca

Find us on social media